Jan 12, 2026 04:59AM JPMorgan Starts Fulcrum Therapeutics (FULC) at Overweight

Dec 11, 2025 09:50AM Fulcrum Therapeutics (FULC) PT Raised to $18 at Truist Securities

Dec 8, 2025 04:57PM After-hours movers: NVIDIA, Toll Brothers, and more

Dec 8, 2025 08:59AM Fulcrum Therapeutics (FULC) PT Raised to $25 at Stifel

Dec 8, 2025 08:16AM Goldman Sachs Reiterates Early-Stage Biotech Rating on Fulcrum Therapeutics (FULC)

Dec 8, 2025 07:41AM Fulcrum Therapeutics (FULC) PT Raised to $7 at BofA Securities

Dec 8, 2025 07:22AM Fulcrum Therapeutics (FULC) PT Raised at Piper Sandler Post Positive 20mg Pociredir Data

Dec 8, 2025 06:26AM Fulcrum Therapeutics (FULC) PT Raised to $25 at H.C. Wainwright

Dec 8, 2025 04:16AM Fulcrum Therapeutics (FULC) PT Raised to $24 at Leerink Partners

Dec 8, 2025 04:02AM Fulcrum Therapeutics (FULC) PT Raised to $10 at RBC Capital

Nov 24, 2025 07:35AM Truist Securities Starts Fulcrum Therapeutics (FULC) at Buy

Nov 24, 2025 06:38AM Fulcrum Therapeutics (FULC) PT Raised to $18 at H.C. Wainwright

Nov 19, 2025 02:14PM Fulcrum stock surges as rival’s sickle cell drug trial disappoints

Oct 29, 2025 07:32AM Fulcrum Therapeutics Inc. (FULC) Misses Q3 EPS by 2c

Oct 21, 2025 04:11AM Fulcrum Therapeutics (FULC) PT Raised to $20 at Leerink Partners

Oct 20, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Fulcrum Therapeutics (FULC)

Oct 8, 2025 05:24AM Fulcrum Therapeutics (FULC) PT Raised to $16 at Leerink Partners

Oct 3, 2025 07:47AM Cantor Fitzgerald Reiterates Overweight Rating on Fulcrum Therapeutics (FULC)

Oct 1, 2025 06:08AM Oppenheimer Reiterates Outperform Rating on Fulcrum Therapeutics (FULC)

Jul 30, 2025 07:55AM Fulcrum Therapeutics (FULC) PT Raised to $5 at RBC Capital

Jul 29, 2025 11:35AM H.C. Wainwright Upgrades Fulcrum Therapeutics (FULC) to Buy

Jul 29, 2025 07:28AM Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 1c

Jul 29, 2025 06:48AM Fulcrum Therapeutics reports Q2 results, pociredir trial data

Jun 20, 2025 06:58AM Cantor Fitzgerald Reiterates Overweight Rating on Fulcrum Therapeutics (FULC)

May 23, 2025 06:21AM Leerink Partners Upgrades Fulcrum Therapeutics (FULC) to Outperform

May 1, 2025 07:54AM Fulcrum Therapeutics Inc. (FULC) Misses Q1 EPS by 2c

Nov 14, 2024 12:37AM Fulcrum Therapeutics Inc. (FULC) Tops Q3 EPS by 5c

Sep 24, 2024 04:09PM Fulcrum Therapeutics Inc. (FULC) will reduce its workforce

Sep 12, 2024 10:58AM BofA Securities Downgrades Fulcrum Therapeutics (FULC) to Underperform

Sep 12, 2024 10:39AM Stifel Downgrades Fulcrum Therapeutics (FULC) to Hold

Sep 12, 2024 06:55AM Fulcrum Therapeutics (FULC) Reports Topline Results from Phase 3 REACH Trial of Losmapimod

Sep 9, 2024 06:11AM BofA Securities Upgrades Fulcrum Therapeutics (FULC) to Neutral

Sep 3, 2024 07:18AM Fulcrum Therapeutics (FULC) PT Raised to $15 at RBC Capital

Aug 19, 2024 07:02AM Fulcrum Therapeutics Inc. (FULC) Appoints Isabel Kalofonos as Chief Commercial Officer, Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

Jul 31, 2024 07:30AM Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 128c